5,398.50
+1.92%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alkem Laboratories
Its shares trade on NSE under the ticker ALKEM.NS. It has been listed since 23 December 2015. In the fiscal year to 31 March 2026, it reported revenue of ₹147.12bn and net income of ₹23.02bn. At that date it held total assets of ₹208.73bn and shareholders' equity of ₹138.20bn.
Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2015-12-23. The firm is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The firm operates through pharmaceuticals segment. The firm produces generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and approximately 50 countries internationally. The firm offers its products across various therapeutic areas, such as anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, Rheumatology, central nervous system (CNS), oncology, urology and gynecology. The firm offers its products under various brands, including Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Gemcal, Taxim, Sumo, Maxvoid Plus, Tamsukem Plus and Neurokem NT. The firm has approximately 20 manufacturing facilities, of which 18 manufacturing facilities are located in India and two in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Dec 2015
- Employees
- 16,966
- Website
- alkemlabs.com ↗
Leadership
Pay as last reported
- Mr. Basudeo SinghExecutive Chairman of the Board, since 2021₹214.3m
- Dr. Vikas GuptaChief Executive Officer₹108.6m
- Mr. Nitin AgrawalPresident - Finance, Chief Financial Officer₹14.4m
- Mr. Manish NarangPresident - Legal, Chief Compliance Officer, Company Secretary, since 2020₹18.3m
- Mr. Sandeep SinghManaging Director, Executive Director, since 2017₹97.5m
- Mrs. Madhurima SinghExecutive Director, since 2021₹110.9m
- Mr. Mritunjay SinghExecutive Director₹123.6m
- Mr. Sarvesh SinghExecutive Director, since 2019₹48.7m
- Mr. Srinivas SinghExecutive Director, since 2022₹106.1m
- Mr. Narendra AnejaIndependent Director₹3.8m
- Ms. Neela BhattacherjeeIndependent Director
- Mr. Diwakar GuptaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 69
- Social
- 50
- Governance
- 24
- Direct emissions (scope 1)
- 19,249 t
- Energy emissions (scope 2)
- 82,319 t
- Value chain emissions (scope 3)
- 365,176 t
- Women in the workforce
- 2.55851%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alkem Laboratories Ltd has several strengths that contribute to its success in the pharmaceutical industry. These include:
Weaknesses
- Despite its strengths, Alkem Laboratories Ltd faces certain weaknesses that could potentially hinder its performance:
Opportunities
- Alkem Laboratories Ltd can capitalize on the following opportunities to further enhance its business growth:
Threats
- Alkem Laboratories Ltd must also be cautious of potential threats that could impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.